Fadi Braiteh, MD, Comprehensive Cancer Centers of Nevada

Weigh nivolumab–ipilimumab benefits versus immune toxicities in HCC, factoring patient comorbidities, access, preferences, and the urgent need for predictive biomarkers.

In HCC, CheckMate-9DW shows nivolumab–ipilimumab preserves quality of life; early immune toxicities are common but manageable without losing

Frontline HCC experts weigh atezolizumab-bevacizumab, STRIDE, and nivolumab-ipilimumab, using ALBI and social support to guide safer choices.

Frontline HCC therapy choices weigh immunotherapy regimens, ALBI liver function and support needs, highlighting gaps for Child-Pugh B/C patients.

In HCC, IMbrave050 tempers adjuvant atezo-bev hopes as final data weakens RFS gains, highlighting unmet need and new trials.

For HCC with portal vein invasion, experts urge baseline EGD for varices to guide anti-VEGF use and reduce bleeding risk.

Experts break down first-line unresectable HCC choices—STRIDE, atezo/bev, nivo/ipi—balancing cirrhosis, comorbidities, and immunotherapy risks.

Dual-checkpoint HCC toxicities peak weeks 3–15; experts share monitoring and steroid-first hepatitis management, plus cautious rechallenge strategies and emerging IL‑6 approaches.